BioPharm America™ 2012 program is full-to-brimming with top life science CEOs
Carlsbad, CA and Boston, MA – July 31, 2012: BioPharm America™, to be held September 19–21, 2012 in Boston, MA has an unprecedented program line-up featuring top CEOs for what will be the most influential US life science partnering event of 2012. EBD Group, the leading partnering firm for the life science industry, will hold the annual event at the Westin Boston Waterfront in collaboration with the Massachusetts Biotechnology Council (MassBio).
"BioPharm America is well-established as the leading North American life science partnering event," said Carola Schropp, President of EBD Group. "The deals that have previously been made at this event have had an incredibly positive impact on the year-end prospectus for our attending biotech and pharma executives. They count on us to bring them face-to-face with the best the industry has to offer."
"The landscape for biopharma companies is changing with new laws and a greater focus on patient needs," said David Meeker, CEO of Genzyme, a Sanofi company. "What worked in the past to make Genzyme a global biotechnology leader based in Massachusetts, may not work today. I look forward to sharing thoughts on innovation and partnering opportunities with others at BioPharm America."
Wednesday's opening plenary session "Who is the best player in the value chain?" will be moderated by Doug Cole of Flagship Ventures with speakers Robert J. Gould of Epizyme; Mike Poole of AstraZeneca; Terry Porter of Takeda Pharmaceuticals; and Philip Vickers of Shire HGT.
"This topic will ensure a lively discussion," said Robert J. Gould, Epizyme's President and CEO. "Biotechs have demonstrated the ability to deliver innovative research, but we have often relied on pharma partners to bring those discoveries through clinical development and beyond. Emerging strategies, like the creation of personalized therapeutics for patients with genetically defined diseases, now enable innovation in business models as well. It will be interesting to explore the potential for biotechs to once again drive their products through development and to the market."
Thursday's keynote panel "From start-up to commercial company and the challenges in between: Could we do it again today?" will be moderated by industry expert Karen Bernstein of BioCentury. Speakers include Geoff MacKay of Organogenesis; David Meeker of Genzyme, a Sanofi company; and Richard Pops of Alkermes.
"Partnering is one of the most critical tools to offset the cost associated with R&D. We will discuss innovation in pharmaceutical development and how collaborations have changed the way we do business," said Richard Pops, CEO of Alkermes.
Adding suspenseful fun to the program, Wednesday's spotlight panel "Let's make a deal because 'Biotech has talent'" will give delegates in the audience 30 seconds to pitch their company, product, technology or service to a star-studded panel of judges representing big pharma. Moderator Douglas MacDougall of MacDougall Biomedical Communications will call upon delegates to present to the jury made up of John Gustofson of AstraZeneca; Tomas Landh of Novo Nordisk; James O'Mara of Ironwood Pharmaceuticals; Deanna Petersen of Shire; and John Sorvillo of Amgen. The first and second place winners will receive a full 30-minute private one-to-one meeting with the panelist of their choice.
The program topics cover pressing issues for industry insiders, from spotlight panels covering innovative partnerships in field of immunotherapy, pre-competitive collaborations, emerging markets and global drug development strategies, to a discussion on best deal structures. The business development track includes pharma/venture hybrid funds, financing models and a critical review of major deals of the past year.
Again this year, BioPharm America will celebrate the announcement of the Fierce 15, selected for their pioneering technology and innovative business models, with John Carroll, Editor-in-Chief of FierceBiotech, set to lead a discussion with several Fierce 15 CEOs on the current landscape in life sciences.